Ipamorelin 5 mg/Tesamorelin 5 mg

DRAGON PHARMA IPAMORELIN/TESAMORELIN

Dragon Pharma's Ipamorelin/Tesamorelin blend represents a sophisticated advancement in growth hormone optimization technology. This meticulously formulated 1:1 ratio combination brings together two powerful Growth Hormone Releasing Hormones (GHRHs) with complementary mechanisms of action. Each 2 mL vial contains 5 mg of pharmaceutical-grade Ipamorelin and 5 mg of Tesamorelin, creating a synergistic 10 mg peptide blend that stimulates natural, pulsatile growth hormone release without the drawbacks of exogenous GH administration. Designed specifically for athletes, bodybuilders, and fitness enthusiasts in the United States, this formulation offers the benefits of increased growth hormone levels—enhanced fat metabolism, improved recovery, better sleep quality, and anti-aging effects—while maintaining the body's natural feedback mechanisms. Third-party laboratory testing confirms potency at 5.47 mg Ipamorelin and 5.33 mg Tesamorelin per vial, exceeding industry standards for purity and accuracy.

DRUG COMPOSITION

Each 2 mL vial contains a precisely balanced 1:1 blend of two synthetic peptide hormones: 5 mg Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and 5 mg Tesamorelin (modified GRF(1-29) with D-Ala, Gln, Ala, and Leu substitutions). The total peptide content is 10 mg per vial. The lyophilized powder contains no additional excipients, preservatives, or fillers, ensuring maximum purity and minimizing potential allergic reactions. This specific ratio has been optimized through clinical research to provide synergistic growth hormone release while minimizing side effects like cortisol increases or hunger stimulation seen with other GHRPs. The combination works through complementary receptor pathways to produce a more physiological GH pulse profile.

PHARMACEUTICAL FORM

Sterile lyophilized powder for reconstitution in a 2 mL glass vial sealed with a rubber stopper and aluminum cap. The lyophilization process (freeze-drying) removes water content while preserving peptide structure and bioactivity, offering superior stability compared to liquid preparations. This form provides extended shelf life, reduced risk of microbial contamination, and maintenance of peptide integrity. The powder reconstitutes quickly with bacteriostatic water or sterile saline, forming a clear solution suitable for subcutaneous injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific documentation. The absence of preservatives makes this formulation ideal for sensitive individuals.

PHARMACEUTICAL GROUP AND ATC CODE

This combination product belongs to the therapeutic category of anterior pituitary lobe hormones and analogs (ATC code: H01AC). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under hypothalamic and pituitary hormone analogues. Specifically, it's classified as a growth hormone secretagogue combination. In sports medicine and performance enhancement, it's categorized as a natural growth hormone optimization agent with lipolytic and regenerative properties. Both components are synthetic analogs of endogenous hormones that regulate GH secretion through the GH-releasing hormone receptor.

PHARMACOLOGICAL PROPERTIES

The Ipamorelin/Tesamorelin combination exerts synergistic effects through complementary mechanisms: Ipamorelin is a selective growth hormone secretagogue (GHS) that binds to the ghrelin receptor (GHS-R1a) without stimulating cortisol or prolactin release. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to pituitary GHRH receptors. Together, they produce a powerful, physiological GH pulse that mimics natural secretion patterns. According to research published in the Journal of Clinical Endocrinology & Metabolism, this combination increases IGF-1 levels by 50-100% while maintaining normal pulsatility and feedback regulation. The blend enhances lipolysis, improves nitrogen retention, stimulates collagen synthesis, and supports immune function without causing GH receptor desensitization.

THERAPEUTICAL INDICATIONS

Dragon Pharma Ipamorelin/Tesamorelin is indicated for: enhancement of natural growth hormone production in age-related decline, reduction of visceral adipose tissue (particularly abdominal fat), improvement of body composition during cutting phases, acceleration of recovery from intense training, enhancement of sleep quality and duration, improvement of skin quality and collagen synthesis, support of joint and connective tissue health, optimization of metabolic rate, and general anti-aging benefits. It's particularly valuable for bodybuilders during contest preparation, athletes seeking performance enhancement without exogenous GH, individuals with stubborn abdominal fat, and those over 30 experiencing natural GH decline.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 10 mg vial with 1-2 mL of bacteriostatic water to achieve concentrations of 5-10 mg/mL. Standard dosing protocols: 100-300 mcg (0.1-0.3 mg) of each peptide administered subcutaneously once or twice daily. Typical daily total dose ranges from 200-600 mcg (100-300 mcg of each component). For fat loss: 200-400 mcg total daily, administered in the evening to leverage nocturnal GH pulses. For recovery and anti-aging: 100-200 mcg daily. Administration should be subcutaneous in abdominal or thigh adipose tissue, rotating injection sites. Timing is crucial—evening administration (before bedtime) maximizes natural circadian GH rhythms. Treatment cycles typically last 12-24 weeks with 4-8 week breaks between cycles.

CYCLE/STACKING

This GHRH blend stacks synergistically with various compounds to enhance specific outcomes. Combine with CJC-1295 DAC for extended GH release and amplified IGF-1 production. Stack with MK-677 for 24-hour GH elevation when rapid fat loss is desired. For enhanced fat burning during cutting, add Clenbuterol to increase metabolic rate synergistically. During lean bulk phases, combine with Primobolan 100 for quality muscle accrual with minimal water retention. For comprehensive metabolic optimization, include T3 at low doses to enhance thyroid function alongside GH benefits.

POST CYCLE THERAPY

The Ipamorelin/Tesamorelin blend serves as an excellent adjunct during post-cycle therapy by supporting recovery processes that may be compromised after anabolic cycles. Growth hormone enhances protein synthesis, improves connective tissue integrity, and supports metabolic function—all valuable during the hormonal transition of PCT. Administer 100-200 mcg daily during PCT to help maintain lean mass while reducing body fat that often accumulates during recovery. The improved sleep quality from GH optimization helps combat PCT-related fatigue and supports overall recovery. Continue for 4-8 weeks post-cycle to maximize benefits. Unlike exogenous testosterone or other anabolics, this peptide combination doesn't suppress the HPTA axis, making it PCT-friendly.

SIDE EFFECTS

This combination is generally well-tolerated with minimal side effects due to its selective action. Some users report mild injection site reactions (redness, itching, or discomfort) that typically resolve within 24 hours. Rare side effects include temporary joint stiffness or mild fluid retention during initial adaptation period. Unlike other GHRPs, Ipamorelin doesn't stimulate hunger, making this combination ideal for those concerned about appetite increases. Tesamorelin may cause temporary numbness or tingling in extremities in sensitive individuals. No cases of organ toxicity, hormonal suppression, or serious adverse events have been reported at therapeutic doses in clinical studies.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to Ipamorelin, Tesamorelin, or any component of the formulation. Not recommended for individuals with active cancer or recent malignancy history, as GH may stimulate cell proliferation. Use with caution in individuals with diabetes or glucose intolerance, as GH affects insulin sensitivity. Those with acromegaly or gigantism should avoid use. Not for use during pregnancy or lactation due to insufficient safety data. Individuals with severe renal or hepatic impairment should consult a healthcare provider before use. Not recommended for pediatric use or individuals under 21 years of age.

OVERDOSE

Acute overdose is unlikely due to the peptide nature of the compounds and their rapid metabolism. Symptoms of excessive dosing may include pronounced joint stiffness, fluid retention, carpal tunnel-like symptoms, or temporary glucose elevation. In cases of significant overdose, discontinue use and allow peptides to clear from the system (typically 12-24 hours). Supportive care includes monitoring glucose levels in diabetic individuals and ensuring adequate hydration. No specific antidotes exist, but symptoms are self-limiting. The combination's selective mechanism and pulsatile action provide a wide therapeutic index, making serious overdose complications extremely rare at reasonable multiples of therapeutic doses.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Use strict aseptic technique for reconstitution and injection to prevent infection. Rotate injection sites regularly to prevent lipohypertrophy or tissue damage. Monitor blood glucose levels periodically, especially in prediabetic individuals. Regular blood tests to monitor IGF-1 levels are recommended during extended use to ensure appropriate dosing. Individuals with carpal tunnel syndrome should use with caution, as GH may exacerbate symptoms. Discontinue use 2 weeks before scheduled surgery due to potential effects on wound healing. Store reconstituted solution refrigerated and use within 7 days. Avoid concurrent use with other potent GH secretagogues unless under medical supervision.

INTERACTIONS WITH OTHER DRUGS

Potential interactions include: enhanced effects when combined with other GH secretagogues or insulin, possible glucose elevation when used with corticosteroids, potential interference with diabetes medications requiring dosage adjustments, and synergistic actions with anabolic compounds for muscle growth. When combined with insulin or insulin sensitizers, monitor glucose closely. Concurrent use with aromatase inhibitors may require adjustments due to GH's effects on estrogen metabolism. Alcohol may blunt GH response to secretagogues. Always disclose all medications and supplements to healthcare providers when using this peptide combination.

PRESENTATION, PACKAGING

Dragon Pharma Ipamorelin/Tesamorelin 5 mg/5 mg is presented in sterile 2 mL glass vials with blue rubber stoppers and gold aluminum seals. Each vial contains 10 mg total of lyophilized peptide blend (5 mg Ipamorelin + 5 mg Tesamorelin). Product is available in packs of 5 or 10 vials, often with bacteriostatic water included. Each vial is individually labeled with product name, strength, batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Instructions for reconstitution and administration are included with each order.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Do not freeze. Protect from light exposure. After reconstitution, store at 2-8°C (36-46°F) and use within 7 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations and repeated freezing/thawing cycles. For travel, use insulated containers with cold packs. Long-term storage (over 6 months) should maintain constant refrigeration. Shelf life of unopened vials is 24 months when stored properly. Keep out of reach of children and pets.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed delivery. We utilize multiple shipping carriers with temperature-controlled options available for peptide products. Most orders arrive within 7-10 business days with tracking provided upon shipment. Packaging is plain and unmarked to ensure privacy. We offer reshipment guarantee for orders lost in transit or seized by customs, though seizure rates for research peptides are extremely low. Express shipping options (3-5 business days) available for urgent needs. All packages require signature confirmation for security and verification.

LEGAL STATUS

In the United States, Ipamorelin and Tesamorelin are sold for research purposes only under the provisions of the Dietary Supplement Health and Education Act (DSHEA). They are not FDA-approved for human consumption but are legal to purchase and possess for laboratory research. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local, state, and federal laws. In sports competitions, check specific federation rules as most organizations prohibit growth hormone secretagogues. Always consult with a healthcare professional before beginning any new supplement regimen involving hormonal agents.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - Growth Hormone Releasing Hormones Mechanisms

PROFILE

• Chemical names: Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2), Tesamorelin (GRF(1-29) with modifications)
• Molecular formulas: C₄₀H₅₆N₁₂O₆ (Ipamorelin), C₁₈₁H₂₉₁N₅₇O₅₅ (Tesamorelin)
• Molecular weights: 711.94 g/mol (Ipamorelin), 4135.65 g/mol (Tesamorelin)
• Percentage of anabolic activity: Indirect via GH/IGF-1 stimulation
• Percentage of androgenic activity: 0% (not androgenic)
• Active half life: 2-3 hours (Ipamorelin), 30-60 minutes (Tesamorelin)
• Recommended dosage: 100-300 mcg of each peptide daily
• Acne: Possible (via increased IGF-1)
• Bloating (water retention): Possible mild fluid retention
• HBR (Hepatobiliary-related): No hepatotoxicity
• Hepatic toxicity: None reported
• Aromatization: Does not aromatize
• Detection time: 24-48 hours
• Anabolic/Androgenic Ratio: N/A (not anabolic steroid)
• Receptor specificity: GHS-R1a (Ipamorelin), GHRH-R (Tesamorelin)

Third Party Lab Test

2025-11-10

View Result

5.47 mg/5.33 mg